Arcadia Biosciences (RKDA) has recently revealed a barrage of very positive developments which will result in near-term commercial revenues in multiple product lines. As exciting as this news is, however, I think the bigger point is that these developments validate the company's technology platform and push RKDA to the forefront of pure-play genome-editing agricultural plays.
Before I review the recent developments, let me remind readers of my previous coverage of RKDA, including a survey of the industry in which I compare RKDA to its peers as well as a write-up looking at the